FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Falchook, G. S. [1 ]
Zhou, X. [2 ]
Rosen, L. S. [3 ]
Venkatakrishnan, K. [2 ]
Kurzrock, R. [1 ]
Mahalingam, D. [4 ]
Goldman, J. [5 ]
Jung, J. [6 ]
Milch, C. [2 ]
Sarantopoulos, J. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Millennium Pharmaceut Inc, Clin Pharmacol, Cambridge, MA USA
[3] Premiere Oncol, Oncol, Santa Monica, CA USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA
[5] UCLA Med Ctr, David Geffen Sch Med, Div Hematol Oncol, Santa Monica, CA USA
[6] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [21] A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
    Olszanski, Anthony J.
    Middleton, Mark R.
    Bahleda, Rastilav
    Heist, Rebecca Suk
    Rangachari, Lakshmi
    Zhou, Xiaofei
    Bozon, Viviana
    Kneissl, Michelle
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
    Cervantes-Ruiperez, A.
    Elez, M. E.
    Rosello, S.
    Macarulla, T.
    Rodriguez-Braun, E.
    Lee, Y.
    Ecsedy, J.
    Liu, H.
    Fingert, H.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] MLN8237 (ALISERTIB), AN INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING CASTRATION-RESISTANT PROSTATE CANCER (CRPC) RECEIVING A STANDARD DOCETAXEL REGIMEN: PRELIMINARY PHASE 1 RESULTS
    Hahn, N. M.
    Sarantopoulos, J.
    Higano, C.
    Zhou, X.
    Zhang, B.
    Leonard, E. J.
    Benaim, E.
    Graff, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 303 - 304
  • [24] Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)-An Investigational Aurora A Kinase Inhibitor-in Patients with Advanced Hematologic Malignancies
    Kelly, Kevin R.
    Padmanabhan, Swaminathan
    Goy, Andre
    Berdeja, Jesus G.
    Reeder, Craig B.
    McDonagh, Kevin T.
    Zhou, Xiaofei
    Danaee, Hadi
    Xiao, Hugh
    Benaim, Ely
    Shea, Thomas C.
    BLOOD, 2011, 118 (21) : 1061 - 1062
  • [25] Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)
    Goldberg, Stuart L.
    Fenaux, Pierre
    Craig, Michael D.
    Gyan, Emmanuel
    Lister, John
    Kassis, Jeannine
    Pigneux, Arnaud
    Schiller, Gary J.
    Jung, JungAh
    Leonard, E. Jane
    Fingert, Howard
    Westervelt, Peter
    BLOOD, 2010, 116 (21) : 1341 - 1341
  • [26] Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
    Venkatakrishnan, Karthik
    Kim, Tae Min
    Lin, Chia-Chi
    Thye, Lim Soon
    Chng, Wee Joo
    Ma, Brigette
    Chen, Ming Huang
    Zhou, Xiaofei
    Liu, Hua
    Kelly, Virginia
    Kim, Won Seog
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 942 - 953
  • [27] Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
    Manfredi, Mark G.
    Ecsedy, Jeffrey A.
    Chakravarty, Arijit
    Silverman, Lee
    Zhang, Mengkun
    Hoar, Kara M.
    Stroud, Stephen G.
    Chen, Wei
    Shinde, Vaishali
    Huck, Jessica J.
    Wysong, Deborah R.
    Janowick, David A.
    Hyer, Marc L.
    Leroy, Patrick J.
    Gershman, Rachel E.
    Silva, Matthew D.
    Germanos, Melissa S.
    Bolen, Joseph B.
    Claiborne, Christopher F.
    Sells, Todd B.
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7614 - 7624
  • [28] Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
    Huynh, Jasmine
    Chen, Justin
    Kim, Edward Jae-Hoon
    Gandara, David R.
    Semrad, Thomas John
    Riess, Jonathan W.
    Li, Tianhong
    Wu, Chun-Yi
    Zhang, Chao
    Yu, Aiming
    Matsukuma, Karen
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
    Karthik Venkatakrishnan
    Tae Min Kim
    Chia-Chi Lin
    Lim Soon Thye
    Wee Joo Chng
    Brigette Ma
    Ming Huang Chen
    Xiaofei Zhou
    Hua Liu
    Virginia Kelly
    Won Seog Kim
    Investigational New Drugs, 2015, 33 : 942 - 953
  • [30] Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
    Kim, Edward Jae-hoon
    Semrad, Thomas John
    Gandara, David R.
    Riess, Jonathan
    Li, Tianhong
    Yu, Aiming
    Matsukuma, Karen
    Mack, Philip C.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345